Clinical trial
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
NCT00083226 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00083226 |
|---|---|
| Title | Doxorubicin and Bortezomib in Treating Patients With Liver Cancer |
| Official title | A Phase II Trial of Bortezomib Plus Doxorubicin in Hepatocellular Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer |
| Intervention type | Drug |
| Interventions | doxorubicin, bortezomib |
| Enrollment | 42 |
| Start date | Mar 1, 2004 |
| Primary completion | Feb 1, 2011 |
| Completion | Aug 1, 2012 |
| First posted | May 17, 2004 |
| Last update posted | Oct 30, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: